I'm a pharmacoepidemiologist researching medication safety and clinical outcomes. This blog explains my research in clear, accessible terms — exploring what the evidence really means for patients and clinicians.
Four independent lines of evidence — meta-analysis, Mendelian randomisation, and two pharmacovigilance databases — converge on the same conclusion: the finasteride-depression signal is an artefact of study design and stimulated reporting, not pharmacology. The warning itself may be causing more harm than the risk it describes.
15 min readA deep dive into my meta-analysis on 5-alpha reductase inhibitors and depression risk. Why some studies overestimated the risk by 200% and what this means for patients taking finasteride or dutasteride.
12 min readNew evidence from South Korea's national health database sheds light on whether finasteride and dutasteride affect diabetes risk. Using robust active-comparator methods, we found minimal to no increased risk.
10 min readDoes finasteride affect blood sugar control in men with type 2 diabetes? Using New Zealand's national pharmaceutical data, we compared long-term outcomes between finasteride and tamsulosin users.
8 min read